Table I. Patient clinical data and summary of epitopes detected

SPC	Time Point	Age (y)	Sex	Rx	Coinfection	CD4	CD8	VL	HIV Tetramer	TRAF1 Increased?
16123	Baseline	50	M	Yes	No	364	699	<40	A2 (SL9)	Yes
	Week 12					981	1335	<40
31209	Baseline	49	M	Yes	No	263	1118	<40	A2 (SL9, ILKE)	No
	Week 12					661	2663	<40
31427	Baseline	30	M	Yes	No	274	293	<40	A2 (SL9, ILKE)	Yes
	Week 12					836	768	<40
16206	Baseline	38	M	Yes	No	191	699	<40	B7 (FPRI)	Yes
	Week 12					441	1648	<40
31210	Baseline	32	M	Yes	No	162	604	<40	A2 (SL9)	No
	Week 12					485	1292	<40
31231	Baseline	42	M	Yes	No	365	588	<40	A2 (SL9)	No
	Week 12					838	979	<40
31208	Baseline	41	M	Yes	No	191	350	<40	B7 (FPRI)	No
	Week 12					662	1342	<40
31213	Baseline	45	M	Yes	No	457	342	<40	B7 (FPRI)	Yes
	Week 12					747	929	<40
31206	Baseline	53	M	Yes	No	338	591	<40	B57 (KAFS)	No
	Week 12					451	729	<40
16207	Baseline	55	M	Yes	No	155	1553	<40	B57 (KAFS)	Yes
	Week 12					282	2435	<40

Summary of patient data including age, sex, treated (Rx), and CD4 and CD8 T cell counts before and 12 wk after first IL-7 treatment. HIV tetramer indicates population identified in the study participants. A2 epitopes were SL9 or ILKE, B7 (FPRI), and B57 (KAFS) as described in Materials and Methods; where both are listed, study participants had both HIV-specific CD8 T cell populations.
M, male; SPC, study participant code; VL, viral load.